Cellectis S.A. (CLLS) stock

CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 20, 2026Score 3/30

$1.18−0.15 (-11.28%)

Close on Nov 13, 2026Market cap $118.40MP/E –Yield –

Cellectis profit margin

Profit margin (net margin) is net income as a percentage of revenue.

For fiscal 2025 it was -92.7%, against -88.6% the year before. The highest annual figure on record is -40.8% in fiscal 2015.

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	-92.7%	−4.1
FY2024	Dec 31, 2024	-88.6%	+13296.7
FY2023	Dec 31, 2023	-13385.3%	−12831.7
FY2022	Dec 31, 2022	-553.6%	−177.3
FY2021	Dec 31, 2021	-376.3%	−217.5
FY2020	Dec 31, 2020	-158.8%	+513.3
FY2019	Dec 31, 2019	-672.1%	−54.0
FY2018	Dec 31, 2018	-618.1%	−223.6
FY2017	Dec 31, 2017	-394.5%	−244.4
FY2016	Dec 31, 2016	-150.1%	−109.3
FY2015	Dec 31, 2015	-40.8%	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q2 FY2025	Jun 30, 2025	-141.9%	+215.3
Q2 FY2024	Jun 30, 2024	-313.5%	+799.0
Q2 FY2023	Jun 30, 2023	-6577.0%	−3673.6
Q2 FY2022	Jun 30, 2022	-1449.6%	–
Q2 FY2021	Jun 30, 2021	-357.2%	–
Q2 FY2020	Jun 30, 2020	-1112.5%	–
Q2 FY2019	Jun 30, 2019	-2903.4%	–